Publication Name	World Journal of Hepatology
Manuscript ID	112835
Country	China

Category	Gastroenterology & Hepatology
Manuscript Type	Basic Study
Article Title	He-He-Shu-Yang formula alleviates liver fibrosis by inhibiting hepatic stellate cell activation in vivo and in vitro
Manuscript Source	Unsolicited Manuscript
All Author List	Fo-Lai Zeng, Mei-Jie Shi, You-Sheng Mo, Huan-Ming Xiao, Yu-Bao Xie and Xiao-Ling Chi
Funding Agency and Grant Number	Funding Agency Grant Number Guangdong Basic and Applied Basic Research Fund Project No. 2022A1515110825 and No. 2023A1515011092 the Incubation Program for the Science and Technology Development of Chinese Medicine, Guangdong Laboratory No. HQL2024PZ033 Chi Xiaoling National Famous Traditional Chinese Medicine Expert Inheritance Studio, Teaching Letter from the State Traditional Chinese Medicine Office[2022] No. 75 Advantage Disease Project of Guangdong Provincial Hospital of Traditional Chinese Medicine[2020] No. 37 Science and Technology Planning Project of Guangdong Province No. 2023B1212060063 Project of Guangdong Provincial Key Laboratory of Chinese Medicine for Prevention and Treatment of Refractory Chronic Diseases No. YN2023MB04 Clinical Research Projects of Guangdong Provincial Hospital of Chinese Medicine No. YN2022QN05 Guangzhou Basic Research Program for Young Doctors in Basic and Applied Basic Research No. 2024A04J3004
Corresponding Author	Xiao-Ling Chi, Chief Physician, Department of Hepatology, Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, No. 111 Dade Road, Guangzhou 510120, Guangdong Province, China. chixiaolingqh@163.com
Key Words	He-He-Shu-Yang formula; Liver fibrosis; Mechanism; Hepatic stellate cells; Nicotinamide adenine dinucleotide phosphate oxidase 4 pathway; Reactive oxygen species pathway
Core Tip	High-performance liquid chromatography identified six key components in He-He-Shu-Yang formula (HHSY) that are effective in reducing liver fibrosis. HHSY has a definite therapeutic effect on liver fibrosis in vivo and in vitro models. HHSY’s mechanism may be through the inhibition of hepatic stellate cell activation via the nicotinamide adenine dinucleotide phosphate oxidase 4/reactive oxygen species/nucleotide binding oligomerization domain-like receptor family pyrin domain-containing 3 pathways.
Citation	Zeng FL, Shi MJ, Mo YS, Xiao HM, Xie YB, Chi XL. He-He-Shu-Yang formula alleviates liver fibrosis by inhibiting hepatic stellate cell activation in vivo and in vitro. World J Hepatol 2025; In press

Received	2025-08-08 06:57
Peer-Review Started	2025-08-08 06:57
To Make the First Decision
Return for Revision	2025-08-27 08:23
Revised	2025-09-10 04:26
Second Decision	2025-11-12 02:45
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2025-11-13 02:21
Articles in Press	2025-11-13 02:21
Publication Fee Transferred	2025-09-15 03:16
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	1948-5182 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com